세계의 중재적 종양학 시장 - 규모, 점유율, 동향 분석 보고서 : 기술별, 수기별, 최종 용도별, 지역별, 부문 예측(2024-2030년)

Interventional Oncology Market Trends

The global interventional oncology market size was estimated at USD 4.09 billion in 2023 and is projected to grow at a CAGR of 10.27% from 2024 to 2030. This growth can be attributed to the increasing prevalence of cancer, increasing technological advancements in minimally invasive procedures, growing geriatric population, rising focus on early cancer detection, and increasing public and private investments in the field of interventional oncology. There is a significant rise in the number of cancer cases globally, increasing the need for advanced solutions facilitating better cancer care According to the World Health Organization data published in February 2022, cancer accounted for around 10 million deaths in 2020, causing 1 in every 6 deaths globally.

The rising global incidence of cancer is largely attributed to increasing tobacco use, unhealthy diets, alcohol consumption, air pollution, and physical inactivity. This surge in cancer cases poses a significant challenge for healthcare systems, spurring the development of advanced solutions that offer better results and outcomes. Interventional oncology, which provides a minimally invasive alternative to traditional cancer treatments such as surgery, radiation, and chemotherapy, has become increasingly popular. Its advantages in terms of reduced patient trauma and quicker recovery times are key factors driving market growth.

These staggering statistics highlight the urgent need for effective cancer treatments. Interventional oncology, with its array of minimally invasive techniques such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and cryoablation, offers significant advantages over traditional surgery, including reduced recovery times and lower complication rates. As the global cancer burden continues to rise, the adoption of these advanced interventional techniques is expected to accelerate, driven by their ability to improve patient outcomes and quality of life.

Companies in the interventional oncology market are actively pursuing various strategies to develop advanced solutions aimed at improving patient treatment and care. For example, in April 2021, Terumo launched its global therapeutic interventional oncology team to achieve excellence in interventional oncology solutions, with the goal of enhancing patient quality of life and survival rates. Such initiatives are expected to spur the development of innovative solutions, increasing the adoption of interventional oncology and driving market growth.

Moreover, increased efforts to develop advanced solutions have led to significant investments from both government and private organizations. In June 2023, Royal Philips announced that the Philips-coordinated IMAGIO consortium of clinical partners received a grant of approximately $25.97 million. This funding is intended to support research on minimally invasive cancer treatments, with a focus on liver cancer, lung cancer, and soft tissue sarcomas. Such investments are crucial for advancing interventional oncology technologies and improving patient outcomes.

Technique Insights

The ablation therapies segment held the largest market share in 2023. Ablation therapies, including radiofrequency, microwave, cryoablation, and laser ablation, are gaining popularity due to their minimally invasive nature and their effectiveness in targeting tumours with minimal damage to surrounding tissues. These therapies offer a promising alternative to traditional cancer treatments such as surgery and radiation, providing patients with shorter recovery times, reduced pain, and fewer complications. With an increasing number of cancer cases each year, there is a growing demand for effective and less invasive treatment options. According to the World Health Organization, cancer is one of the leading causes of death worldwide, and the number of new cases is expected to rise significantly in the coming decades. This escalating burden of cancer is propelling the adoption of innovative treatment modalities like ablation therapies.

The embolization therapies segment is anticipated to witness a significant CAGR over the forecast period. Embolization therapies, which involve the selective occlusion of blood vessels to cut off the blood supply to tumors, are increasingly recognized for their efficacy in treating various types of cancer, particularly liver cancer. These minimally invasive procedures offer significant advantages over traditional surgical approaches, including reduced recovery times, decreased complications, and the ability to target tumors that are otherwise inoperable. The growing preference for minimally invasive procedures among patients and healthcare providers is also contributing to the market's expansion. Embolization therapies are typically performed on an outpatient basis, resulting in shorter hospital stays, lower healthcare costs, and quicker recovery times compared to traditional surgery. This preference aligns with the broader trend towards cost-effective and patient-centric healthcare solutions, making embolization an attractive option for cancer treatment.

Global Interventional Oncology Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global interventional oncology market report based on technique, procedure, application, end use, and region.

• Technique Outlook (Revenue, USD Million, 2018 - 2030)
• Ablation Therapies

Radiofrequency Ablation (RFA)

Microwave Ablation (MWA)

Cryoablation

Laser Ablation

Irreversible Electroporation (IRE)

• Embolization Therapies

Transarterial Chemoembolization (TACE)

Transarterial Radioembolization (TARE)

• Biopsy Techniques

Core Needle Biopsy

Fine Needle Aspiration (FNA)

• Targeted Therapy Delivery Systems

Drug-Eluting Beads

Radioembolization

Drug-Eluting Stents

Injectable Hydrogels and Nanoparticles

Other Targeted Therapy Systems

• Image-Guided Procedures

Ultrasound Guidance

CT Scan Guidance

MRI Guidance

Fluoroscopy Guidance

• Procedure Outlook (Revenue, USD Million, 2018 - 2030)
• Tumor Ablation
• Tumor Biopsy
• Vascular Interventions
• Palliative Care
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Liver Cancer
• Lung Cancer
• Kidney Cancer
• Prostate Cancer
• Breast Cancer
• Other Cancer
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Specialty Clinics
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

• Latin America

Brazil

Argentina

• MEA

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Technique Segment
  • 1.2.2. Procedure Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Interventional Oncology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Increasing technological advancements in minimally invasive procedures
    • 3.2.1.3. Growing geriatric population
    • 3.2.1.4. Increasing focus on early cancer detection
    • 3.2.1.5. Increasing public and private investments in the field of interventional oncology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with interventional oncology
    • 3.2.2.2. Requirement of highly skilled professionals
• 3.3. Interventional Oncology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Interventional Oncology Market: Technique Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Interventional Oncology Market Product & Service Movement Analysis
• 4.3. Global Interventional Oncology Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
• 4.4. Ablation Therapies
  • 4.4.1. Ablation Therapies market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Radiofrequency Ablation (RFA)
    • 4.4.2.1. Radiofrequency Ablation (RFA) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Microwave Ablation (MWA)
    • 4.4.3.1. Microwave Ablation (MWA) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Cryoablation
    • 4.4.4.1. Cryoablation market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Laser Ablation
    • 4.4.5.1. Laser Ablation market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Irreversible Electroporation (IRE)
    • 4.4.6.1. Irreversible Electroporation (IRE) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Embolization Therapies
  • 4.5.1. Embolization Therapies market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Transarterial Chemoembolization (TACE)
    • 4.5.2.1. Transarterial Chemoembolzation (TACE) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Transarterial Radioembolization (TARE)
    • 4.5.3.1. Transarterial Radioembolization (TARE) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Biopsy Techniques
  • 4.6.1. Biopsy Techniques market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.2. Core Needle Biopsy
    • 4.6.2.1. Core Needle Biopsy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.3. Fine Needle Aspiration (FNA)
    • 4.6.3.1. Fine Needle Aspiration (FNA) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Targeted Therapy Delivery Systems
  • 4.7.1. Drug Delivery Systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.2. Drug-Eluting Beads
    • 4.7.2.1. Drug-Eluting Beads market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.3. Radioembolization
    • 4.7.3.1. Radioembolization market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.4. Drug-Eluting Stents
    • 4.7.4.1. Drug-Eluting Stents market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.5. Injectable Hydrogels and Nanoparticles
    • 4.7.5.1. Injectable Hydrogels and Nanoparticles market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.6. Other Targeted Therapy Systems
    • 4.7.6.1. Other Targeted Therapy Systems market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Image-Guided Procedures
  • 4.8.1. Image-Guided Procedures market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.2. Ultrasound Guidance
    • 4.8.2.1. Ultrasound Guidance market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.3. CT Scan Guidance
    • 4.8.3.1. CT Scan Guidance market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.4. MRI Guidance
    • 4.8.4.1. MRI Guidance market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.5. Fluoroscopy Guidance
    • 4.8.5.1. Fluoroscopy Guidance market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Interventional Oncology Market: Procedure Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Interventional Oncology Market Procedure Movement Analysis
• 5.3. Global Interventional Oncology Market Size & Trend Analysis, by Procedure, 2018 to 2030 (USD Million)
• 5.4. Tumor Ablation
  • 5.4.1. Tumor Ablation market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Tumor Biopsy
  • 5.5.1. Tumor Biopsy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Vascular Interventions
  • 5.6.1. Vascular Interventions market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Palliative Care
  • 5.7.1. Palliative Care market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Interventional Oncology Materials Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Interventional Oncology Market Application Movement Analysis
• 6.3. Global Interventional Oncology Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Liver Cancer
  • 6.4.1. Liver Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Lung Cancer
  • 6.5.1. Lung Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Kidney Cancer
  • 6.6.1. Kidney Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Prostate Cancer
  • 6.7.1. Prostate Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Breast Cancer
  • 6.8.1. Breast Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Other Cancer
  • 6.9.1. Other Cancer market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Interventional Oncology Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Interventional Oncology Market End Use Movement Analysis
• 7.3. Global Interventional Oncology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Specialty Clinics
  • 7.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Interventional Oncology Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Competitive scenario
    • 8.4.1.3. Regulatory framework
    • 8.4.1.4. Reimbursement scenario
    • 8.4.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Competitive scenario
    • 8.4.2.3. Regulatory framework
    • 8.4.2.4. Reimbursement scenario
    • 8.4.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Competitive scenario
    • 8.4.3.3. Regulatory framework
    • 8.4.3.4. Reimbursement scenario
    • 8.4.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Competitive scenario
    • 8.5.1.3. Regulatory framework
    • 8.5.1.4. Reimbursement scenario
    • 8.5.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Competitive scenario
    • 8.5.2.3. Regulatory framework
    • 8.5.2.4. Reimbursement scenario
    • 8.5.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Competitive scenario
    • 8.5.3.3. Regulatory framework
    • 8.5.3.4. Reimbursement scenario
    • 8.5.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Competitive scenario
    • 8.5.4.3. Regulatory framework
    • 8.5.4.4. Reimbursement scenario
    • 8.5.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Competitive scenario
    • 8.5.5.3. Regulatory framework
    • 8.5.5.4. Reimbursement scenario
    • 8.5.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Norway
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Competitive scenario
    • 8.5.6.3. Regulatory framework
    • 8.5.6.4. Reimbursement scenario
    • 8.5.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Competitive scenario
    • 8.5.7.3. Regulatory framework
    • 8.5.7.4. Reimbursement scenario
    • 8.5.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Competitive scenario
    • 8.5.8.3. Regulatory framework
    • 8.5.8.4. Reimbursement scenario
    • 8.5.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Competitive scenario
    • 8.6.1.3. Regulatory framework
    • 8.6.1.4. Reimbursement scenario
    • 8.6.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Competitive scenario
    • 8.6.2.3. Regulatory framework
    • 8.6.2.4. Reimbursement scenario
    • 8.6.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Competitive scenario
    • 8.6.3.3. Regulatory framework
    • 8.6.3.4. Reimbursement scenario
    • 8.6.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Competitive scenario
    • 8.6.4.3. Regulatory framework
    • 8.6.4.4. Reimbursement scenario
    • 8.6.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Competitive scenario
    • 8.6.5.3. Regulatory framework
    • 8.6.5.4. Reimbursement scenario
    • 8.6.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Competitive scenario
    • 8.6.6.3. Reimbursement scenario
    • 8.6.6.4. Regulatory framework
    • 8.6.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Competitive scenario
    • 8.7.1.3. Regulatory framework
    • 8.7.1.4. Reimbursement scenario
    • 8.7.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Competitive scenario
    • 8.7.2.3. Regulatory framework
    • 8.7.2.4. Reimbursement scenario
    • 8.7.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Competitive scenario
    • 8.8.1.3. Regulatory framework
    • 8.8.1.4. Reimbursement scenario
    • 8.8.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Competitive scenario
    • 8.8.2.3. Regulatory framework
    • 8.8.2.4. Reimbursement scenario
    • 8.8.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Competitive scenario
    • 8.8.3.3. Regulatory framework
    • 8.8.3.4. Reimbursement scenario
    • 8.8.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Competitive scenario
    • 8.8.4.3. Regulatory framework
    • 8.8.4.4. Reimbursement scenario
    • 8.8.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2023
• 9.4. Company Profiles/Listing
  • 9.4.1. Medtronic plc
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Boston Scientific Corporation
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Johnson & Johnson (Ethicon)
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Baxter International Inc.
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Cook Medical
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. C.R. Bard Inc. (Acquired by BD)
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. AngioDynamics Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Stryker Corporation
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. B. Braun Melsungen AG
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Terumo Corporation
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Siemens Healthineers
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. GE Healthcare
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives